Global News

RepliCel Life Sciences restructures

Monday, April 11, 2016

RepliCel Life Sciences, a clinical stage regenerative medicine company focused on the development of autologous cell therapies, has announced that its Board of Directors has authorized a plan to downsize all non-critical programs and staff in an effort to preserve capital to focus on the following three essential priorities pending a major financing or corporate transaction: (1) continued protection of intellectual property, (2) assembling of data from the RCT-01 and RCS-01 clinical trials expected near year-end 2016, and (3) the completion of a licensing/co-development transaction related to one of the four products the Company has in development.

[Read More]

Pfizer, IBM collaboration on Parkinson’s disease care

Monday, April 11, 2016

Pfizer and IBM have announced a first-of-its-kind research collaboration to develop innovative remote monitoring solutions aimed at transforming how clinicians deliver care to patients suffering from Parkinson’s disease. The experimental approach will rely on a system of sensors, mobile devices, and machine learning to provide real-time, around-the-clock disease symptom information to clinicians and researchers. The ultimate goal is to obtain a better understanding of a patient’s disease progression and medication response to help inform treatment decisions and clinical trial design, while also speeding the development of new therapeutic options.

[Read More]

Eric Morrie joins ClinCapture as director, Product Operations

Monday, April 11, 2016

Eric Morrie joins ClinCapture as director of Product Operations, bringing with him 20 years of experience in the clinical trial industry, including at some of the world’s leading pharmaceutical and medical device companies. The new addition to the executive management team brings ClinCapture’s experience and skill set to a new level.

[Read More]

Sosei subsidiary Heptares and Allergan partner

Thursday, April 7, 2016

Sosei Group‘s wholly-owned subsidiary Heptares Therapeutics has entered into a definitive agreement with Allergan Pharmaceuticals International, a wholly owned subsidiary of Allergan, a global pharmaceutical company, under which Allergan will license exclusive global rights to a broad portfolio of novel subtype-selective muscarinic receptor agonists in development for the treatment of major neurological disorders, including Alzheimer’s disease.

[Read More]

Medidata acquires Intelemage

Wednesday, April 6, 2016

Medidata, a global provider of cloud-based solutions for clinical research in life sciences, has announced the acquisition of Intelemage, a global pioneer in medical image sharing and workflow management. Medidata will integrate Intelemage’s technology into its SaaS platform, the Medidata Clinical Cloud, offering customers an end-to-end solution to capture, manage and analyze medical imaging data. The transaction was completed in the second quarter of 2016.

[Read More]